JamesPDeanMDPhD

Genitourinary Oncology, Hematologic Oncology

Executive Medical Director, Oncology Development, AbbVie (Pharmacyclics)

Dr. Dean is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. James Dean is an Oncologist specializing in Drug Development in Hematologic Oncology. His education includes a fellowship in Medical Oncology at Fred Hutchinson Cancer Research Center/University of Washington, residency in Internal Medicine at SUNY Stony Brook, and a MD, PhD from the University of Iowa. Professionally, he currently serves as Executive Medical Director at AbbVie (Pharmacyclics). He has held several significant roles in his career, including positions at CTI Biopharma Corp, Seattle Genetics, Inc, UW Medicine/University of Washington Medical Center, and Fred Hutchinson Cancer Research Center. He has expertise in conditions such as hematologic oncology (CLL, DLBCL, MCL, FL, myelofibrosis), prostate cancer, and bladder cancer. He has also contributed significantly to medical literature, including extensive work in chronic lymphocytic leukemia treatment.

University of WashingtonFellowship, Hematology and Medical Oncology, 2003 - 2006
Stony Brook Medicine/University HospitalResidency, Internal Medicine, 2000 - 2003
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 2000

PubMed

Abstracts/Posters

Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
James P. Dean, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019